BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/15/2019 7:45:48 AM | Browse: 1087 | Download: 2065
 |
Received |
|
2019-05-20 06:29 |
|
Peer-Review Started |
|
2019-05-23 09:47 |
|
First Decision by Editorial Office Director |
|
2019-07-31 03:49 |
|
Return for Revision |
|
2019-08-20 00:39 |
|
Revised |
|
2019-09-03 13:42 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-09-12 10:23 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-09-13 04:54 |
|
Articles in Press |
|
2019-09-13 04:54 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-10-24 12:09 |
|
Publish the Manuscript Online |
|
2019-11-15 07:45 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Se Jun Park, Hyunho Kim, Kabsoo Shin, Myung Ah Lee and Tae Ho Hong |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Myung Ah Lee, MD, PhD, Professor, Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea, 222 Banpo-daero, Secho-gu, Seoul 16509, South Korea. angelamd@catholic.ac.kr |
| Key Words |
Pancreatic cancer; Gemcitabine-refractory; Capecitabine; S-1; Second-line treatment; |
| Core Tip |
To date, there is no standard regimen for patients with gemcitabine-refractory pancreatic cancer with poor performance status. In this study, we compared the efficacy and toxicity of capecitabine and S-1 for such patients. The median progression free survival was longer in the S-1 group than in the capecitabine group; however, there were no statistical differences in their overall survival. Among grade 3 or 4 toxicity, hand-foot syndrome was significantly more common in the capecitabine group than in the S-1 group. Thus, oral chemotherapy can be considered as a second-line treatment in gemcitabine-refractory pancreatic cancer patients with poor performance status. |
| Publish Date |
2019-11-15 07:45 |
| Citation |
Park SJ, Kim HH, Shin KS, Hong TH, Lee MA. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030
|
| URL |
https://www.wjgnet.com/1948-5204/full/v11/i11/1021.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v11.i11.1021 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
